Chemo Research Sl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CHEMO RESEARCH SL
CHEMO RESEARCH SL has two approved drugs.
There are seven US patents protecting CHEMO RESEARCH SL drugs.
There are seventeen patent family members on CHEMO RESEARCH SL drugs in nine countries and one supplementary protection certificate in one country.
Summary for Chemo Research Sl
| International Patents: | 17 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Chemo Research Sl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | 8,946,276 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chemo Research Sl | BENZNIDAZOLE | benznidazole | TABLET;ORAL | 209570-002 | Aug 29, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | 8,658,678 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | 8,877,792 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | 7,893,097 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Chemo Research Sl | BENZNIDAZOLE | benznidazole | TABLET;ORAL | 209570-001 | Aug 29, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Chemo Research Sl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2016200825 | ⤷ Start Trial |
| Mexico | 381271 | ⤷ Start Trial |
| Argentina | 070406 | ⤷ Start Trial |
| China | 107823123 | ⤷ Start Trial |
| China | 103763925 | ⤷ Start Trial |
| Brazil | 112013033759 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Chemo Research Sl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0328535 | 96C0021 | Belgium | ⤷ Start Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
